Cardiex

Cardiex Limited is an Australian medical technology company that specializes in digital health solutions for assessing cardiovascular and vascular diseases. The company is publicly listed on the Australian Securities Exchange (ASX: CDX) and is known for its proprietary SphygmoCor® vascular biosensing technology, which is FDA-cleared and utilized in over 4,500 installations globally at major medical and research institutions. Cardiex focuses on noninvasive patient monitoring devices that measure arterial health through digital vascular biomarkers, including central blood pressures and arterial stiffness. Their product portfolio features the SphygmoCor XCEL, a device for assessing central aortic pressure waveforms, and the CONNEQT Pulse, a connected vascular biometric monitor designed for both home and clinical use. Cardiex's solutions are employed in clinical trials and healthcare systems worldwide, aiming to improve cardiovascular health outcomes through actionable data analytics. The company has experienced significant growth, with annual revenue reaching $12.4 million in 2024, reflecting its expanding market presence.

• Employees 26
• Founded 2005
• Annual Revenue $4107000
• Total Funding $26180000